Both clinician-rated and patient-reported outcomes suggested that mindfulness-based stress reduction (MBSR) was well-tolerated with comparable effectiveness to the first-line medication escitalopram for patients with anxiety disorders in a US randomized clinical trial. The trial included 276 participants (women 75%, men 25%; mean age 33 years; Asian 19%, Black 15%, Hispanic […]
In the prespecified analysis of a randomized, double-blind, placebo-controlled trial, bempedoic acid reduces LDL cholesterol, high-sensitivity C-reactive protein, and risk of cardiovascular events among those with baseline diabetes, prediabetes, or normoglycemia, with or without cardiovascular disease at baseline. Between Dec 22, 2016, and Nov 7, 2022, 13 970 patients who were […]
A prospective, randomized, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-controlled trial concluded that a 800 mg/day pharmaceutical-grade Chondroitin sulfate (CS) is superior to placebo and similar to celecoxib in reducing pain and improving function over 6 months in symptomatic knee osteoarthritis (OA) patients. The trial included 604 patients of knee osteoarthritis in […]